News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
LAEKNA (02105.HK) Phase III Breast Cancer Trial Meets Primary Endpoint with Significant PFS Improvement
LAEKNA-B (02105.HK) announced that LAE002 (afuresertib) in combination with fulvestrant has achieved strong and positive topline results in the Phase III clinical trial "AFFIRM-205...
Reset
Send
The window will close in 5 seconds
LAEKNA (02105.HK) Phase III Breast Cancer Trial Meets Primary Endpoint with Significant PFS Improvement
Close
Recommend
2
Positive
5
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

LAEKNA-B (02105.HK)  -0.530 (-3.072%)    Short selling $342.77K; Ratio 1.711%   announced that LAE002 (afuresertib) in combination with fulvestrant has achieved strong and positive topline results in the Phase III clinical trial "AFFIRM-205". The study targeted patients with HR+/HER2- locally advanced or metastatic breast cancer ("LA/mBC") harboring PIK3CA/AKT1/PTEN alterations who experienced disease progression following prior endocrine therapy with or without CDK4/6 inhibitors.

This pivotal study successfully met its primary endpoint. In terms of progression-free survival (PFS), the combination therapy demonstrated a highly statistically significant and clinically meaningful improvement compared with the control group.

The Phase III clinical trial (AFFIRM-205) is a multicenter, randomized, double-blind, placebo-controlled pivotal study designed to evaluate the anti-tumor efficacy and safety of the combination therapy. A total of 261 subjects were enrolled, of whom 70.5% had previously received CDK4/6 inhibitor treatment. (ec/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-22 12:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.